Therapy of Inflammatory Bowel Disease using New 5-ASA Compounds: An Introduction
Strong evidence has been accumulating that mesalazine (5- aminosalicylic acid, 5-ASA) represents the therapeutic moiety of the standard drug sulphasalazine. Since the active metabolite avoids the toxic potential of sulphapyridine, this perception has initiated new therapeutic approaches, for example...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1989-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1989/434838 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|